Health Care • Medical Specialities
$11.05 ▼ -1.21
(-9.87%)
MKT CAP: $116.5M • VOL: 29.8K
52W L $7 52W H $42
BNR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $77.2M | $70.7M | $75.7M |
| YoY Revenue Growth % | +9.2% | -6.6% | — |
| Gross Profit | $57.6M | $49.6M | — |
| Gross Margin % | 74.7% | 70.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.8M | -$49.0M | -$94.3M |
| Operating Margin % | -10.2% | -69.3% | -80.0% |
| Net Income (GAAP) | -$7.9M | -$47.5M | -$92.1M |
| EBITDA (Normalized) | -$7.2M | -$48.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.1M | -$12.6M | -$36.0M |
| Capital Expenditures (CapEx) | $751.0K | $742.0K | — |
| Free Cash Flow (FCF) | -$4.8M | -$13.4M | -$36.0M |
| FCF Margin % | -6.2% | -18.9% | -47.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $68.4M | $71.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $76.5M | $79.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BNR.